Sandoz Group AG develops, manufactures and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars and biotechnology manufacturing services and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Sandoz Group AG is based in Rotkreuz, Switzerland.
| Revenue (Most Recent Fiscal Year) | $10.36B |
| Net Income (Most Recent Fiscal Year) | $1.00M |
| PE Ratio (Current Year Earnings Estimate) | 16.91 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | 0.94 |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.88 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 20.02 |
| Pre-Tax Margin (Trailing 12 Months) | -0.11% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | 1.24 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.79 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.57 |
| Inventory Turnover (Trailing 12 Months) | 1.95 |
| Book Value per Share (Most Recent Fiscal Quarter) | $18.56 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | $2.71 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 440.00M |
| Free Float | -- |
| Market Capitalization | $23.54B |
| Average Volume (Last 20 Days) | 0.03M |
| Beta (Past 60 Months) | 0.58 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 0.06% |
| Annual Dividend (Based on Last Quarter) | $0.44 |
| Dividend Yield (Based on Last Quarter) | 0.82% |